Just when CBD products seem to be inching towards some sort of regulation that can finally open up the market, one of the category's biggest backers thus far is pulling out. As we've reported over the past few years, Southern Glazer's has been eagerly recruiting partners for its growing portfolio of hemp-infused beverages. Back in 2021, as it picked up contracts with brands like Mad Tasty, Kill Cliff and DEFY, and later with major Canadian producers Tilray and Canopy Growth, the distributor's eagerness to step into the uncertain market seemed to represent a vote of confidence for wary retailers, investors and mainstream consumers that still may be wary of the category's long term potential. But in a press release last week, Canadian brand CENTR, distributed in California by Southern Glazer's since 2021, announced that the distributor had unceremoniously pulled out of the CBD category in the U.S. altogether. With no official confirmation coming from Southern Glazer's, which hasn't returned our calls, we can only speculate for the moment as to the distributor's motivations for turning away from CBD, if indeed that's what they've done. For a company stocked with sales reps making a living moving alcohol, spending time developing a new category with uneven traction across retail customers may not have been a great fit. Partnering with brands like B GREAT and Charlotte's Web introduced non-beverage formats like gummies and tinctures into the mix as well. Internal changes in management roles may have also come into play. Meanwhile, here's what we've been hearing: Speaking to BevNET yesterday, John Timar, former CEO of Kill Cliff, an early pioneer in mass-market CBD drinks that teamed with Southern Glazer's for distribution in 2021, noted that the brand had "mutually exited" its agreement as part of a strategy pivot from retail back towards e-commerce. He's no longer involved in the day-to-day business, but he noted that Southern Glazer's supposed exit comes at a time in which optimism is running high for a legislative solution to the persistent question around CBD. A bipartisan group in Congress is currently conducting requests for information (RFIs) for hemp-derived CBD products, signaling a potential legislative path around inaction by the Food and Drug Administration (FDA). ONE HEMP, a coalition of CBD brands (including Charlotte's Web) "dedicated to addressing the FDA’s concerns with a data and science-backed approach," said it made "meaningful progress" during a recent presentation of findings to Congress. In other words: change may be coming, but not soon enough. "The lack of having a regulatory framework to open it up for retailers and normalize it for consumers and allow for all the other things you need has definitely stymied the potential and growth for the industry," said Timar. "I wouldn't be surprised if there were organizations who are just fatigued at this point, and are either mitigating the risk in the near-term by not putting more capital behind it or just pulling out because their patience is over." We'll continue to track this story as it develops. |